BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11600361)

  • 1. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
    Rodriguez-Cerrato V; McCoig CC; Michelow IC; Ghaffar F; Jafri HS; Hardy RD; Patel C; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3092-7. PubMed ID: 11600361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.
    Rodriguez-Cerrato V; Ghaffar F; Saavedra J; Michelow IC; Hardy RD; Iglehart J; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3098-103. PubMed ID: 11600362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
    Ostergaard C; Sørensen TK; Knudsen JD; Frimodt-Møller N
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1706-12. PubMed ID: 9661008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin in the therapy of experimental pneumococcal meningitis.
    Schmidt H; Dalhoff A; Stuertz K; Trostdorf F; Chen V; Schneider O; Kohlsdorfer C; Brück W; Nau R
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1397-407. PubMed ID: 9624483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition kinetics of moxifloxacin in lactating ewes.
    Goudah A
    Vet J; 2008 Nov; 178(2):282-7. PubMed ID: 17900948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical microbiology profile of moxifloxacin.
    Krasemann C; Meyer J; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S51-63. PubMed ID: 11249830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.
    Lutsar I; Ahmed A; Friedland IR; Trujillo M; Wubbel L; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2414-7. PubMed ID: 9371342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.
    Lutsar I; Friedland IR; Wubbel L; McCoig CC; Jafri HS; Ng W; Ghaffar F; McCracken GH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2650-5. PubMed ID: 9756771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis.
    Scotton PG; Pea F; Giobbia M; Baraldo M; Vaglia A; Furlanut M
    Clin Infect Dis; 2001 Nov; 33(9):e109-11. PubMed ID: 11577376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
    Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B
    Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
    Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
    J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis.
    Sipahi OR; Turhan T; Pullukcu H; Calik S; Tasbakan M; Sipahi H; Arda B; Yamazhan T; Ulusoy S
    J Antimicrob Chemother; 2008 Mar; 61(3):670-3. PubMed ID: 18230687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra high-pressure liquid chromatographic assay of moxifloxacin in rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles.
    Jain GK; Jain N; Pathan SA; Akhter S; Talegaonkar S; Chander P; Khar RK; Ahmad FJ
    J Pharm Biomed Anal; 2010 May; 52(1):110-3. PubMed ID: 20045276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis.
    Fernández A; Cabellos C; Tubau F; Maiques JM; Doménech A; Ribes S; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2005 Jan; 55(1):78-83. PubMed ID: 15546968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.